Cabozantinib: A narrative drug review

Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively searched various websites, including the United S...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research, statistics, and treatment (Online) statistics, and treatment (Online), 2023-01, Vol.6 (1), p.74-87
Main Authors: Srigadha, Vivek, Prabhash, Kumar, Noronha, Vanita, Joshi, Amit, Patil, Vijay, Menon, Nandini, Singh, Ajay, Shah, Minit
Format: Article
Language:English
Subjects:
cabozantinib
differentiated thyroid
hepatocellular carcinoma
medullary thyroid cancer
renal cell carcinoma
tyrosine kinase inhibitor
vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c316t-d2b294bad5e8d52eb2f0a67b1c502b5f19a3228bcc3430a88625537dff96324d3
cites cdi_FETCH-LOGICAL-c316t-d2b294bad5e8d52eb2f0a67b1c502b5f19a3228bcc3430a88625537dff96324d3
container_end_page 87
container_issue 1
container_start_page 74
container_title Cancer research, statistics, and treatment (Online)
container_volume 6
creator Srigadha, Vivek
Prabhash, Kumar
Noronha, Vanita
Joshi, Amit
Patil, Vijay
Menon, Nandini
Singh, Ajay
Shah, Minit
description Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively searched various websites, including the United States Food and Drug Administration, the European Medicine Agency Drug Manual, PubMed, Science Direct, and UpToDate using the search terms, "cabozantinib," "renal cell carcinoma," "hepatocellular carcinoma," "differentiated thyroid cancer," and "medullary thyroid cancer." We shortlisted all the full-text articles published between 2011 and 2022. Out of a total of 788 manuscripts identified, we included 52. This review of cabozantinib details the pharmacodynamics, pharmacokinetics, clinical indications, adverse effects, safety, and the key research trials that investigated the use of cabozantinib. We have discussed the available clinical trial data and real-world outcomes, both with respect to the efficacy and safety of cabozantinib.
doi_str_mv 10.4103/crst.crst_9_23
format article
fullrecord <record><control><sourceid>wolterskluwer_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_60dbfe1f74954885a9c291f2b9902830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_60dbfe1f74954885a9c291f2b9902830</doaj_id><sourcerecordid>10.4103/crst.crst_9_23_74_Cabozant</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-d2b294bad5e8d52eb2f0a67b1c502b5f19a3228bcc3430a88625537dff96324d3</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRsNRePefiMXV3ZjfJepFS_IKCFz0v-1nWpols0gb99fZDe_MyM7zwPgwPIdeMTjmjeGtT10_3Q0kFeEZGICTNEUCcn27ESzLpumgo5yWCQDEiN3Nt2m_d9LGJ5i6bZY1OSfdx6zOXNsss-W30wxW5CLru_OR3j8n748Pb_DlfvD69zGeL3CIr-tyBAcmNdsJXToA3EKguSsOsoGBEYFLvPqqMtciR6qoqQAgsXQiyQOAOx-TlyHWt_lCfKa51-lKtjuoQtGmpdOqjrb0qqDPBs1ByKXhVCS0tSBbASEmhQrpjTY8sm9quSz6ceIyqvTN10HVytivcHwtDW_c-dat6M_ik1t6tmnb4p6VKrv4U4g_mc3b3</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cabozantinib: A narrative drug review</title><source>Medknow Open Access Medical Journals</source><creator>Srigadha, Vivek ; Prabhash, Kumar ; Noronha, Vanita ; Joshi, Amit ; Patil, Vijay ; Menon, Nandini ; Singh, Ajay ; Shah, Minit</creator><creatorcontrib>Srigadha, Vivek ; Prabhash, Kumar ; Noronha, Vanita ; Joshi, Amit ; Patil, Vijay ; Menon, Nandini ; Singh, Ajay ; Shah, Minit</creatorcontrib><description>Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively searched various websites, including the United States Food and Drug Administration, the European Medicine Agency Drug Manual, PubMed, Science Direct, and UpToDate using the search terms, "cabozantinib," "renal cell carcinoma," "hepatocellular carcinoma," "differentiated thyroid cancer," and "medullary thyroid cancer." We shortlisted all the full-text articles published between 2011 and 2022. Out of a total of 788 manuscripts identified, we included 52. This review of cabozantinib details the pharmacodynamics, pharmacokinetics, clinical indications, adverse effects, safety, and the key research trials that investigated the use of cabozantinib. We have discussed the available clinical trial data and real-world outcomes, both with respect to the efficacy and safety of cabozantinib.</description><identifier>ISSN: 2590-3233</identifier><identifier>EISSN: 2590-3225</identifier><identifier>DOI: 10.4103/crst.crst_9_23</identifier><language>eng</language><publisher>Wolters Kluwer India Pvt. Ltd</publisher><subject>cabozantinib ; differentiated thyroid ; hepatocellular carcinoma ; medullary thyroid cancer ; renal cell carcinoma ; tyrosine kinase inhibitor ; vascular endothelial growth factor</subject><ispartof>Cancer research, statistics, and treatment (Online), 2023-01, Vol.6 (1), p.74-87</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-d2b294bad5e8d52eb2f0a67b1c502b5f19a3228bcc3430a88625537dff96324d3</citedby><cites>FETCH-LOGICAL-c316t-d2b294bad5e8d52eb2f0a67b1c502b5f19a3228bcc3430a88625537dff96324d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27458,27924,27925</link.rule.ids></links><search><creatorcontrib>Srigadha, Vivek</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><creatorcontrib>Noronha, Vanita</creatorcontrib><creatorcontrib>Joshi, Amit</creatorcontrib><creatorcontrib>Patil, Vijay</creatorcontrib><creatorcontrib>Menon, Nandini</creatorcontrib><creatorcontrib>Singh, Ajay</creatorcontrib><creatorcontrib>Shah, Minit</creatorcontrib><title>Cabozantinib: A narrative drug review</title><title>Cancer research, statistics, and treatment (Online)</title><description>Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively searched various websites, including the United States Food and Drug Administration, the European Medicine Agency Drug Manual, PubMed, Science Direct, and UpToDate using the search terms, "cabozantinib," "renal cell carcinoma," "hepatocellular carcinoma," "differentiated thyroid cancer," and "medullary thyroid cancer." We shortlisted all the full-text articles published between 2011 and 2022. Out of a total of 788 manuscripts identified, we included 52. This review of cabozantinib details the pharmacodynamics, pharmacokinetics, clinical indications, adverse effects, safety, and the key research trials that investigated the use of cabozantinib. We have discussed the available clinical trial data and real-world outcomes, both with respect to the efficacy and safety of cabozantinib.</description><subject>cabozantinib</subject><subject>differentiated thyroid</subject><subject>hepatocellular carcinoma</subject><subject>medullary thyroid cancer</subject><subject>renal cell carcinoma</subject><subject>tyrosine kinase inhibitor</subject><subject>vascular endothelial growth factor</subject><issn>2590-3233</issn><issn>2590-3225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kE1Lw0AQhhdRsNRePefiMXV3ZjfJepFS_IKCFz0v-1nWpols0gb99fZDe_MyM7zwPgwPIdeMTjmjeGtT10_3Q0kFeEZGICTNEUCcn27ESzLpumgo5yWCQDEiN3Nt2m_d9LGJ5i6bZY1OSfdx6zOXNsss-W30wxW5CLru_OR3j8n748Pb_DlfvD69zGeL3CIr-tyBAcmNdsJXToA3EKguSsOsoGBEYFLvPqqMtciR6qoqQAgsXQiyQOAOx-TlyHWt_lCfKa51-lKtjuoQtGmpdOqjrb0qqDPBs1ByKXhVCS0tSBbASEmhQrpjTY8sm9quSz6ceIyqvTN10HVytivcHwtDW_c-dat6M_ik1t6tmnb4p6VKrv4U4g_mc3b3</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Srigadha, Vivek</creator><creator>Prabhash, Kumar</creator><creator>Noronha, Vanita</creator><creator>Joshi, Amit</creator><creator>Patil, Vijay</creator><creator>Menon, Nandini</creator><creator>Singh, Ajay</creator><creator>Shah, Minit</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20230101</creationdate><title>Cabozantinib: A narrative drug review</title><author>Srigadha, Vivek ; Prabhash, Kumar ; Noronha, Vanita ; Joshi, Amit ; Patil, Vijay ; Menon, Nandini ; Singh, Ajay ; Shah, Minit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-d2b294bad5e8d52eb2f0a67b1c502b5f19a3228bcc3430a88625537dff96324d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>cabozantinib</topic><topic>differentiated thyroid</topic><topic>hepatocellular carcinoma</topic><topic>medullary thyroid cancer</topic><topic>renal cell carcinoma</topic><topic>tyrosine kinase inhibitor</topic><topic>vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Srigadha, Vivek</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><creatorcontrib>Noronha, Vanita</creatorcontrib><creatorcontrib>Joshi, Amit</creatorcontrib><creatorcontrib>Patil, Vijay</creatorcontrib><creatorcontrib>Menon, Nandini</creatorcontrib><creatorcontrib>Singh, Ajay</creatorcontrib><creatorcontrib>Shah, Minit</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer research, statistics, and treatment (Online)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Srigadha, Vivek</au><au>Prabhash, Kumar</au><au>Noronha, Vanita</au><au>Joshi, Amit</au><au>Patil, Vijay</au><au>Menon, Nandini</au><au>Singh, Ajay</au><au>Shah, Minit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cabozantinib: A narrative drug review</atitle><jtitle>Cancer research, statistics, and treatment (Online)</jtitle><date>2023-01-01</date><risdate>2023</risdate><volume>6</volume><issue>1</issue><spage>74</spage><epage>87</epage><pages>74-87</pages><issn>2590-3233</issn><eissn>2590-3225</eissn><abstract>Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively searched various websites, including the United States Food and Drug Administration, the European Medicine Agency Drug Manual, PubMed, Science Direct, and UpToDate using the search terms, "cabozantinib," "renal cell carcinoma," "hepatocellular carcinoma," "differentiated thyroid cancer," and "medullary thyroid cancer." We shortlisted all the full-text articles published between 2011 and 2022. Out of a total of 788 manuscripts identified, we included 52. This review of cabozantinib details the pharmacodynamics, pharmacokinetics, clinical indications, adverse effects, safety, and the key research trials that investigated the use of cabozantinib. We have discussed the available clinical trial data and real-world outcomes, both with respect to the efficacy and safety of cabozantinib.</abstract><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/crst.crst_9_23</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2590-3233
ispartof Cancer research, statistics, and treatment (Online), 2023-01, Vol.6 (1), p.74-87
issn 2590-3233
2590-3225
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_60dbfe1f74954885a9c291f2b9902830
source Medknow Open Access Medical Journals
subjects cabozantinib
differentiated thyroid
hepatocellular carcinoma
medullary thyroid cancer
renal cell carcinoma
tyrosine kinase inhibitor
vascular endothelial growth factor
title Cabozantinib: A narrative drug review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A56%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cabozantinib:%20A%20narrative%20drug%20review&rft.jtitle=Cancer%20research,%20statistics,%20and%20treatment%20(Online)&rft.au=Srigadha,%20Vivek&rft.date=2023-01-01&rft.volume=6&rft.issue=1&rft.spage=74&rft.epage=87&rft.pages=74-87&rft.issn=2590-3233&rft.eissn=2590-3225&rft_id=info:doi/10.4103/crst.crst_9_23&rft_dat=%3Cwolterskluwer_doaj_%3E10.4103/crst.crst_9_23_74_Cabozant%3C/wolterskluwer_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c316t-d2b294bad5e8d52eb2f0a67b1c502b5f19a3228bcc3430a88625537dff96324d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true